Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 997-998

  Besse, B ^a   Soria, J C ^a   Le Chevalier, T ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT NATIONAL DU CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; PACLITAXEL; PEMETREXED; VASCULOTROPIN ANTIBODY; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; TAXOID;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; DISEASE COURSE; FEMALE; LUNG TUMOR; MALE; NOTE; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; PACLITAXEL; SURVIVAL RATE; TAXOIDS;

EID: 25444450662     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi231     Document Type: Editorial

References (13)

1. Delbaldo C, Michiels S, Syz N et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004; 92(4): 70-84.
2. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European Multicenter Trial Including 612 Patients. J Clin Oncol 1994; 12(2): 360-367.
3. Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000; 18(3): 623-631.
4. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22(2): 254-261.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 46(2): 2-8.
6. Belani CP, Lee JS, Socinski MA et al. Randomized Phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16: 1069-1075, 10.1093/annonc/mdi216.
7. Lynch TJ, Bell D, Haber D et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. J Clin Oncol 2005; 23(16s): 622s (abstr. 7006).
8. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A Cooperative Multinational Trial. Ann Oncol 2002; 13(10): 539-549.
9. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22(19): 3852-3859.
10. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095-2103.
11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589-1597.
12. Sandler A, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005; 23 (16s): 2s (abstr. 4).
13. Shepherd FA, Pereira J, Ciuleanu TE et al. Randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial. J Clin Oncol 2004; 22(14s): Abstr. 7022.